Cargando…

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quddos, Fatima, Hubshman, Zachary, Tegge, Allison, Sane, Daniel, Marti, Erin, Kablinger, Anita S., Gatchalian, Kirstin M., Kelly, Amber L., DiFeliceantonio, Alexandra G., Bickel, Warren K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684505/ https://www.ncbi.nlm.nih.gov/pubmed/38017205 http://dx.doi.org/10.1038/s41598-023-48267-2

Ejemplares similares

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Remote Alcohol Monitoring to Facilitate Incentive‐Based Treatment for Alcohol Use Disorder: A Randomized Trial
por: Koffarnus, Mikhail N., et al.
Publicado: (2018)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
por: Ryan, Donna H.
Publicado: (2021)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
por: Vadher, Karan, et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
por: Mody, Reema R., et al.
Publicado: (2023)

The phenotype of recovery IV: Delay discounting predicts perceived stress and a chance locus of control in individuals in recovery from substance use disorders
por: Tomlinson, Devin C., et al.
Publicado: (2020)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Discounting of delayed rewards: Missing data imputation for the 21- and 27-item monetary choice questionnaires
por: Yeh, Yu-Hua, et al.
Publicado: (2023)

Social, clinical, and policy implications of ultra-processed food addiction
por: Gearhardt, Ashley N, et al.
Publicado: (2023)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Estimating the Impact of Tobacco Parity and Harm Reduction Tax Proposals Using the Experimental Tobacco Marketplace
por: Freitas-Lemos, Roberta, et al.
Publicado: (2021)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Effects of 6-month episodic future thinking training on delay discounting, weight loss and HbA1c changes in individuals with prediabetes
por: Epstein, Leonard H., et al.
Publicado: (2022)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Choice Bundling Increases Valuation of Delayed Losses More Than Gains in Cigarette Smokers
por: Stein, Jeffrey S., et al.
Publicado: (2022)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n6i9cmhcluc8d25b31bep1j7pi